JNJ · News · 20260922N

Oncology Product Growth

JOHNSON & JOHNSON · 2026-09-22 · Importance 20 · Surprise 24

Investor confidence in J&J’s pharmaceutical growth is being supported by strong demand for TREMFYA and DARZALEX. These products are helping offset declining STELARA sales as the immunology drug faces portfolio and lifecycle pressure. The reporting indicates that investors are emphasizing growth from newer medicines when evaluating J&J’s outlook. MedTech growth remains slower, with Abiomed sales also declining.

Key facts